Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Major Hormones and Their Functions01:27

Major Hormones and Their Functions

Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Risk in Acromegaly: Reassessing the Evidence and Impact of Biochemical Control.

The Journal of clinical endocrinology and metabolism·2026
Same author

Impact of acromegaly subtypes on survival: results from a large multicenter cohort.

Journal of the Endocrine Society·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Pathogenesis of nonfamilial somatotroph adenomas.

The Journal of clinical endocrinology and metabolism·2026
Same author

Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes.

Pituitary·2026
Same author

Editorial: Advances and challenges in adult-onset craniopharyngioma.

Frontiers in endocrinology·2025

Related Experiment Video

Updated: May 19, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Odelia Cooper1, Shlomo Melmed

  • 1Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Best Practice & Research. Clinical Endocrinology & Metabolism
|August 7, 2012
PubMed
Summary

Clinically silent pituitary adenomas show hormone hypersecretion despite lacking clinical symptoms. Accurate classification impacts patient follow-up and treatment strategies for these tumors.

More Related Videos

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome
12:34

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome

Published on: April 2, 2018

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology
09:48

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology

Published on: February 25, 2022

Related Experiment Videos

Last Updated: May 19, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome
12:34

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome

Published on: April 2, 2018

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology
09:48

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology

Published on: February 25, 2022

Area of Science:

  • Endocrinology
  • Oncology
  • Pathology

Background:

  • Pituitary adenomas are classified by hormone hypersecretion, but some show positive immunostaining despite lacking clinical signs, termed silent functioning adenomas.
  • Common silent subtypes include silent gonadotroph, corticotroph, and somatotroph adenomas, with less common silent prolactinomas and thyrotrophinomas.
  • Accurate classification is crucial as it influences post-surgical follow-up and potential medical therapy.

Purpose of the Study:

  • To review the incidence, clinical behavior, and pathological features of clinically silent pituitary adenomas.
  • To highlight the importance of immunostaining in classifying these tumors.
  • To discuss the implications of silent adenoma classification on patient management.

Main Methods:

  • Review of existing literature on pituitary adenomas.
  • Analysis of clinical presentation and immunohistochemical findings.
  • Correlation of pathological features with clinical behavior.

Main Results:

  • Silent functioning adenomas are a recognized subtype of pituitary adenomas.
  • Immunohistochemical staining is key to identifying cell types in clinically nonfunctioning adenomas.
  • Certain silent adenomas, like silent corticotroph adenomas, may exhibit more aggressive behavior.

Conclusions:

  • Correct classification of silent pituitary adenomas is essential for tailoring patient care.
  • Understanding immunostaining patterns aids in determining appropriate surveillance and treatment.
  • Further research into the specific behaviors of silent adenoma subtypes is warranted.